Celldex (CLDX), a biopharmaceutical company, on Sunday reported positive data from the Phase 1 trial for CDX-622, a bispecific antibody developed to target chronic inflammation by neutralizing alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells through stem cell factor (SCF) starvation. Results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 annual meeting.
The first-in-human Phase 1 trial was a randomized, double-blind, placebo-controlled, dose-escalation study to determine pharmacokinetic and pharmacodynamic activity of CDX-622 over several doses.
The combined neutralization of SCF and TSLP by CDX-622 was studied in the trial, and results show that a rapid, dose-dependent reduction in serum tryptase was observed, indicating tissue mast cells inhibition. The drug exhibited monoclonal antibody-like pharmacokinetics, with good exposure upon sub-cutaneous administration.
No immunogenicity was observed, and the drug was found to be generally well-tolerated at all dose levels.
CDX-622 is being further evaluated in an ongoing Phase 1b proof of mechanism study in treating mild to moderate asthma.
CLDX is currently trading at $31.75, up 1.52%.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.